Mining database for the expression and gene regulation network of JAK2 in skin cutaneous melanoma

Life Sci. 2020 Jul 15:253:117600. doi: 10.1016/j.lfs.2020.117600. Epub 2020 Mar 29.

Abstract

Background: Skin cutaneous melanoma (SKCM) is the most common subtype of skin malignancy, with ever-increasing incidence, mortality, and disease burden. Dysregulation of JAK-STATs signaling pathway is involved in the pathogenesis and progression of cancers, thus affecting the prognosis of cancer patients. The function of JAKs in SKCM is still not clarified.

Methods: A total of five online portal (GEPIA, TIMER, GeneMANIA, LinkedOmics, and GSCALite) is used to mine the expression and gene regulation network JAK2 in SKCM.

Results: JAK2 expression was downregulated in SKCM and significantly associated with pathological stage and the prognosis of patients. The functions of JAK2 and associated genes were primarily involved in the DNA recombination, cell cycle checkpoint, metabolic process, NOD-like receptor signaling pathways, p53 signaling pathway and apoptosis. JAK2 level was significantly correlated with the abundance of immune cells and the level of immune biomarkers. Low expression of JAK2 were resistant to QL-VIII-58, TL-1-85, Ruxolitinib, TG101348 and Sunitinib.

Conclusions: Our results reveal the expression and gene regulation network of JAK2 in skin cutaneous melanoma, providing more evidences about the role of JAK2 in carcinogenesis.

Keywords: Biomarker; JAK2; STAT; Skin cutaneous melanoma.

MeSH terms

  • Antineoplastic Agents / metabolism
  • Antineoplastic Agents / pharmacology*
  • Databases, Nucleic Acid
  • Databases, Protein
  • Gene Expression Regulation, Neoplastic
  • Gene Regulatory Networks / drug effects
  • Humans
  • Janus Kinases / genetics
  • Janus Kinases / metabolism*
  • Melanoma / metabolism*
  • Melanoma, Cutaneous Malignant
  • MicroRNAs / metabolism
  • Models, Biological
  • Nitriles
  • Prognosis
  • Pyrazoles / metabolism
  • Pyrazoles / pharmacology*
  • Pyrimidines
  • Signal Transduction
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / metabolism
  • Sunitinib / metabolism
  • Sunitinib / pharmacology*

Substances

  • Antineoplastic Agents
  • MicroRNAs
  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • ruxolitinib
  • Janus Kinases
  • Sunitinib